A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974
administered on Days 1 and 15 of a 28-day cycle in subjects with solid malignancies that have
progressed following effective therapy or for which no effective therapy exists.